Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study symbols : Lly save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Published: 2024-03-10 (Crawled : 20:20) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.3%
H: 0.61%
C: -2.37%
dermatitis skin study
U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab
Published: 2024-03-08 (Crawled : 12:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
drug food meeting study
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
rns60 stroke presentation positive topline study
Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal
Published: 2024-02-01 (Crawled : 22:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.27%
H: 2.04%
C: 2.02%
corporation series treatment study
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
Published: 2024-01-31 (Crawled : 15:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.84%
H: 2.02%
C: -0.73%
jag201 fda genetic clearance therapy study
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $52.795 -3.02% -3.12% 300K
|
|
| O: 1.59%
H: 1.14%
C: -1.42%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: 1.57%
H: 4.94%
C: 1.54%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -1.95%
BEAM | $22.74 -3.11% -3.21% 1.1M
|
Health Technology
|
| O: 1.88%
H: 0.88%
C: -2.79%
t-cell therapy growth study market
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
ADVM | News | $10.19 -7.36% -7.95% 310K
|
Health Technology
|
| O: -0.69%
H: 2.32%
C: -0.12%
therapy growth study market
Sjogren's Syndrome Market to Register Sustainable Growth During the Study Period (2019-2032), Predicts DelveInsight | Key Players - Horizon Therapeutics, Dompe Farmaceutici, MorphoSys, Resolve Therapeutics, Novartis, Johnson & Johnson
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
IMAB | $1.805 0.28% 0.28% 110K
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: -8.42%
resolve key growth study market
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
Published: 2024-01-04 (Crawled : 09:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.22%
H: 1.78%
C: -1.72%
sit-011 collaboration study
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Published: 2024-01-02 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.02%
H: 0.41%
C: 0.41%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.43%
H: 2.12%
C: 2.03%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.64%
H: 4.97%
C: 4.9%
ibi362 obesity first chinese study
Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-12-20 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.87%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.63%
C: 0.1%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
cancer growth study market
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
Published: 2023-12-12 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
cell meeting leukemia study
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
Published: 2023-12-11 (Crawled : 16:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.61%
H: 0.0%
C: 0.0%
total study tirzepatide
Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
Published: 2023-12-06 (Crawled : 22:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
cancer study market
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period (2019-2032), Predicts DelveInsight
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
treatment show growth study market
Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici
Published: 2023-11-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 3.37%
H: 1.29%
C: 1.29%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 2.62%
H: 0.67%
C: 0.58%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -3.12%
H: 0.61%
C: -0.46%
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -2.2%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.54%
H: 0.0%
C: 0.0%
companies diabetes study market
Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) | DelveInsight
Published: 2023-10-31 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.94%
H: 2.55%
C: 2.55%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -4.18%
H: 0.49%
C: -0.02%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -2.76%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
PLRX | $11.88 -5.11% -5.39% 370K
|
Health Technology
|
| O: -0.2%
H: 3.45%
C: 1.37%
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: -2.27%
H: 2.01%
C: 0.44%
study market
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.